Biovitrum Building the biopharma company of tomorrow

1
BiovitrumBuilding the biopharma company of
tomorrow

• Capital Market Day
• 2 February 2006
• Mats Pettersson, CEO

2
Biovitrum In Brief

• An integrated biopharma company with RD,
  manufacturing and product sales
• Medicines for broad diseases and niche
  indications
• Both small molecules and proteins
• Operations in Sweden and UK
• Steady revenues and strong cash position
• 2005 revenues 930 MSEK
• RD budget around 540 MSEK
• About 500 employees

3
Milestones

• 2001
• Creation of Biovitrum
• Spin out from Pharmacia
• 2002
• Divestment of plasma business
• Partnership with GSK on obesity target
• 2003
• Partnership with Amgen on novel diabetes target
• 2004
• Global manufacturer for Wyeth of hemophilia drug
  ReFacto?
• 2005
• Acquisition of Cambridge Biotechnology (CBT)
• Partnership with Santhera on diabetes treatment
• Acquisition of Arexis
• New flexible RD organization
• Partnership with Syntonix on recombinant factor
  IX
• Partnership with Symphogen on RhD antibodies

2006
4
Our Strategies

• Develop medicines for the treatment of broad
  diseases such as metabolic disorders and
  inflammation as well as niche indications such as
  hemophilia
• Develop both small molecules and proteins
• Combine internal discovery with external project
  sourcing in our core areas
• Bring specialist medicines to the market, seek
  partnerships for primary care projects
• Expand portfolio of marketed specialist medicines
  and sales organization in Europe

5
An Integrated Biopharma Company
Discovery
Development
MS
Manufacturing
15 FTE
80 FTE
170 FTE
205 FTE
Marketing Sales Specialist drugs
Manufacturing process development Protein
drugs
Pre-clinical clinical Small molecules and
proteins
Stockholm (SBT) Cambridge (CBT)
In-licensing and collaborations
Partnering of primary care products
Internal discovery units complemented with
in-licensing and collaborations
MS of proprietary and in-licensed products
Process development and manufacturing of
protein drugs offered to external clients
Capacity demand in Clinical Development to be
met by outsourcing.
6
Profound Biopharmaceutical Experience

• More than 125 protein scientists
• 6 products filed for approval
• More than 30 processes developed
• Over 1000 analytical methods developed
• Developed ReFacto

7
Product Portfolio

• ReFacto? (Wyeth)
• recombinant factor VIII for coagulation disorder
• co-promotion rights in Nordic and MENA
  territories
• Kineret? (Amgen)
• recombinant IL-1 receptor antagonist for RA
• co-promotion rights in the EU
• Mimpara? (Amgen)
• for treatment of hyperparathyroidism
• co-promotion rights in the Nordic territory
• Kepivance? (Amgen)
• for oral mucositis in oncology
• co-promotion rights in the Nordic territory
• Novastan? (Mitsubishi)
• for heparin induced thrombocytopenia type II

8
(No Transcript)
9
Some Key Figures

• SEK million
  2004 2005 (Est.)
• Operating revenues 787 936
• Research and Development expenses 536 582
• Operating profit/loss
  -91 -30
• Net profit/loss
  -39 15
• Liquid funds and short term investments
  1585 1621

Figures adjusted according to IFRS
Excluding capital gain from divestment of real
estates and restructuring
charges
10
Revenues
Amounts in SEK million 2005 2004 change
Licensing and Milestone Revenues 206 142 45 Rese
arch Revenues 55 52 6 ReFacto
Manufacturing 192 168 14 Contract Development
Revenues 225 203 11 Co-promotion 104 91 14 Roy
alty Revenues 156 132 18 Other 0 0 -- Total
Revenues 936 787 19
Re-stated comparison numbers due to
implementing IFRS as of 1 January 2005
11
Summary

• Extensive knowledge and experience in
  pharmaceutical RD
• Both small molecules and proteins
• Highly attractive portfolio
• Mix of potential metabolic disease and
  inflammation blockbusters and niche products
• Validated with partnerships
• Substantial near term revenue potential from own
  launches
• Strong revenue flow
• Expanding marketing sales of specialist
  portfolio in Europe
• Contract assignments within manufacturing and
  process development
• ReFacto profits from manufacture, co-promotion
  and global royalties
• Substantial liquid assets